GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours

doi:10.5306/wjco.v12.i4.195

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10431)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-7) series.

Item

Count

PDF

858

WORD

158

HTML

6355

Figures (1-4)

333

Tables (1-7)

279

Sum=7983

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

287

Download

648

Sum=935

Publishing Process of This Article

Item

Count

Browse

455

Download

1058

Sum=1513

Apr 24, 2021 (publication date) through Aug 27, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines

World J Clin Oncol. Apr 24, 2021; 12(4): 195-216
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.195

Table 6 Most commonly used chemotherapy regimens for thymic carcinoma

Scheme	Drugs
ADOC	Doxorubicin + Cisplatin + Vincristine + Cyclophosphamide
CAP	Cisplatin + Doxorubicin + Cyclophosphamide
PE	Cisplatin + Etoposide
VIP	Etoposide + Ifosfamide + Cisplatin
CODE	Cisplatin + Vincristine + Doxorubicin + Etoposide
Carbo-Px	Carboplatin + Paclitaxel
CAP-GEM	Capecitabine + Gemcitabine

ADOC: Anthropogenic dissolved organic carbon; CAP: Capecitabine; PE: Pulmonary embolism; VIP: Vasoactive intestinal peptide; GEM: Gemcitabine.

Citation: Rico M, Flamarique S, Casares C, García T, López M, Martínez M, Serrano J, Blanco M, Hernanz R, de Ingunza-Barón L, Marcos FJ, Couñago F. GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours. World J Clin Oncol 2021; 12(4): 195-216
URL: https://www.wjgnet.com/2218-4333/full/v12/i4/195.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i4.195